日本化学療法学会雑誌第56巻第1号
|
|
- あつとし こいたばし
- 5 years ago
- Views:
Transcription
1 β β β β β Streptococcus pneumoniaehaemophilus influenzaemoraxella catarrhalismycoplasma pneumoniaechlamydia pneumoniae β Key wordsβ
2 mys nilc laci ngis Table. Assessmentschedule Parameters Patientcharacteristics potm /s s QOL Bodytemperature Sputum volume Sputum color Cough Bacteriologicalexamination Mycoplasma/ Chlamydiaantibodytiter Viralantigentests Clinicallaboratorytests Adverseevents Atinitiationof studytreatment Acuteexacerbationphase Day Day7 Typicaly,onadailybasis Day :Assessmentbytheinvestigator :Assessmentbythepatient :Donewheneverpossible :Assessedandrecordedinthe TreatmentDiary bythepatientoncedaily Re-treatment Stable phase Relapse phase β I β β β
3 Mycoplasma pneumoniae Chlamydia pneumoniae Mycoplasma pneumoniaechlamydia pneumoniae M. pneumoniae C. pneumoniae II β β β β β
4 Patients enrolled: N8 (LVFX: N8, -lactam: N9) Patients evaluated for safety: N8 (LVFX: N96, -lactam: N88) Patients evaluated for efficacy: N9 (LVFX: N9, -lactam: N58) Patients evaluated for QOL: N7 (LVFX: N67, -lactam: N5) Patients excluded from all analyses Patients enrolled outside the study contract period Patients with missing case record cards Patients who used an incorrect antibacterial agent Patients lost to follow-up Patients excluded from efficacy analysis Patients deviating from the eligibility criteria Patients without a Treatment Diary Patients excluded from QOL analysis Patients with missing data for QOL assessment LVFX -lactam Total LVFX -lactam Total LVFX -lactam Total 8 Fig.. Dispositionofthepatients. β β β β β β β β β β β β β β
5 Table. Baselinecharacteristicsofthepatients Gender Variables Male Female Total(%) (85.5) 6(.5) LVFX(%) 6(85.) 8(.7) β -lactam (%) 5(86.) 8(.8) < 65 (7.) 7(9.) 6(.) Age >_ 65< 75 95(8.) 75(9.) (.5) >_ 75 (.6) 79(.) (55.) Height Weight Mean±SD Mean±SD 6.6±7. 5.± ±7. 5.±8.5 6.± ±. Outpatient (89.9) 69(88.9) 5(9.) Inpatient/outpatient Inpatient 5(.) (.) (6.9) Unknown No (.) 8(6.) (7.7) Historyofsmoking Yes 9(85.8) 5(8.8) 8 (9.) Unknown 8 6 Smokingindex Severityoftheinfection (accordingtotheinvestigator) Severityoftheinfection (accordingtotheseverity CriteriaoftheJapanese SocietyofChemotherapy) SeverityofCOPD DurationofCOPD(years) Concomitantdrugs Antibacterialmedication within7dayspriortostudy treatment Lowdoselong-term macrolide therapy Concurentdisease Mean±SD Mild Moderate Severe Unknown Mild Moderate Severe Unknown Mild Moderate Severe VerySevere Unknown Mean±SD No Yes No Yes Unknown No Yes Unknown No Yes,57.9±68.9 (58.) 99(9.9) 5(.) 67(.) (67.9) () 6(.6) 8(.7) 96(9.) (6.7) 7.5±5.5 (9.6) 5(9.) (98.8) (.) (85.) 6(.6) 77(.9) 7(69.),76.±689. (5.) 85(.5) (.) 7(8.8) 6(7.) () 8 (.) 6(.8) 7(8.) (8.) 7.±5.6 7(6.8) 7(69.9) 87(98.9) (.) 6(85.) 8(.7) 6(.9) (68.) 997.±6. (7.7) (.6) (.8) (.5) 6(56.5) () 5(8.8) (6.8) (.) 7(.) 8.±5.5 7(.8) 5(.5) 55(98.) (.8) 9(86.) 8(.) 6(7.6) (7.) No 7(7.) (7.9) 7(67.) Homeoxygentherapy Yes 7(9.9) 55(9.) 8 (.7) Unknown 5 No (6.) 99(6.5) (6.) Historyofvaccination Yes 8(8.6) 6(8.5) (8.9) Unknown No (9.5) 7(9.9) 5(89.) Respiratoryphysiotherapy Yes (9.5) 7(9.) 6(.7) Unknown 6 Bodytemperature < 7. >_ 7.< 7.5 >_ 7.5< 9. >_ 9. (7.7) 87(.9) (.6) 7(.8) 8(.7) 65(.) 9(8.) 6(.) 6(7.6) (7.9) 9(.8) (.7) Severe (5.8) 9(7.) (.) Cough Slight 9(5.8) 98(5.) (5.) None 6(.) (.6) (5.) Statistical Test a) Pe=.869 Pe=.8 Pt=.566 Pt=.5 Pe=.599 Pe=. Pt=. Pe=.8 Pe=.78 Pe=.7 Pt=.7 Pe=.56 Pe=.667 Pe=.895 Pe=.67 Pe=.68 Pe=.96 Pe=.798 Pe=.7 Pe=.59 (Continued)
6 Table. (Continued) Variables Total(%) LVFX(%) β -lactam (%) Statistical Test a) Sputum volume Marked Moderate Slight None (.) 5(6.) 66(6.5). (.) (6.9) 8(5.). 9(5.5) (5.) 8(.). Pe=.699 Sputum color Yelow-green Yelow Lightyelow Whiteorclear (8.) 8(5.) 6(.5) (6.) 7(8.9) (5.9) (.) 7(.) (5.) 5(.) 7(9.) (.) Pe=.69 WBC(/mm ) < 8, >_ 8,<, >_,< 5, >_ 5, Notdetermined 98(6.7) 5(.8) 5(5.) 9(.) 9 75(5.7) 7(.6) 6(8.) 6(.7) 7 (5.) (8.) 7(5.) (6.5) Pe=.5 CRP(mg/dL) <.7 >_.7< 5. >_ 5.< >_ Notdetermined (9.5) 9(56.7) 8(8.) (5.7) 9 8(.) 86(5.) (8.) (8.) 7 (.) (7.7) 8(7.) (6.5) Pe=.657 a) Pe:Fisher sexactprobabilitytest,pt:t-test Efficacy rate (%) LVFX group (N9) -lactam group (N58) COX regression analysis: P Fig.. Timecourseoftheeficacyrates. Streptococcus pneumoniaehaemophilus influenzaemoraxella catarrhalis S. pneumoniaeh. influenzaem. catarrhalis S. pneumoniae H. influenzae H. influenzae β Haemophilus influenzae M. catarrhalis S. pneumoniae Mycoplasma pneumoniaechlamydia pneumoniae Mycoplasma pneumoniae
7 ) Sputum volume ) Sputum color 9 LVFX group (N9) -lactam group (N58) 9 LVFX group (N9) -lactam group (N58) 8 8 Improvement rate (%) Improvement rate (%) COX regression analysis: P. COX regression analysis: P ) Cough ) Body temperature 9 8 LVFX group (N88) -lactam group (N55) 9 8 Improvement rate (%) Improvement rate (%) LVFX group (N58) -lactam group (N9) COX regression analysis: P. COX regression analysis: P Fig.. Time course ofimprovementratesforspecific symptoms (sputum volume,sputum color,cough,and body temperature). Chlamydia pneumoniae β β
8 ) 7.5 ) Efficacy rate (%) 6 5 LVFX group (N65) -lactam group (N) Efficacy rate (%) 6 5 LVFX group (N97) -lactam group (N) COX regression analysis: P.96 COX regression analysis: P Fig.. Eficacyratesstratifiedbythebaselinebodytemperature. ) Mildmoderate (FEV % pred 5) ) Severeextremely severe (FEV % pred 5%) 9 LVFX group (N8) -lactam group (N6) 9 LVFX group (N6) -lactam group (N) Efficacy rate (%) 6 5 Efficacy rate (%) 6 5 COX regression analysis: P.6 COX regression analysis: P Fig.5. EficacyratesstratifiedbytheseverityofCOPD. β III β β
9 ) Time course of QOL ) Improvement of QOL (QOL at each assessment-qol on day ) LVFX group (N67) -lactam group (N5) 5 LVFX group (N67) -lactam group (N5) * * * * * ** ** ** ** VAS 5 VAS Wilcoxon rank-sum test : P.5, : P. Repeated measures ANOVA: P. Wilcoxon rank-sum test : P.5, : P. Repeated measures ANOVA: P Fig.6. EvaluationofQOL. ) Mildmoderate (FEV % pred 5%) ) Severeextremely severe (FEV % pred 5%) 5 LVFX group (N7) -lactam group (N) 5 LVFX group (N9) -lactam group (N6) VAS VAS Wilcoxon rank-sum test : P.5 Repeated measures ANOVA: P.76 Wilcoxon rank-sum test : P.5, : P. Repeated measures ANOVA: P Fig.7. ImprovementofQOLstratifiedbytheseverityofCOPD. Table. Readmissionrate No.ofsubjects Group Patientsreadmited(%) Patientsgivenanantibacterialagent atreadmission(%) LVFX 9 (.5) (6.) β -lactam 58 (.) (9.) Reasonforreadmission:Noimprovementofbaselinesymptoms a) Fisher sexactprobabilitytest Statisticaltest a) P=.88 P=.
10 Percentage of patients with isolated causative bacteria Streptococcus pneumoniae 8.8% (7/8).% (/8) Haemophilus influenzae.% (8/8) Moraxella catarrhalis 5.% (/8) Pseudomonas aeruginosa.% (/8) Haemophilus parainfluenzae 8.8% (7/8) Klebsiella pneumoniae.5% (/8) Other bacteria Gram-positive bacteria Gram-negative bacteria.5% (/8).8% (/8) Fig.8. Isolatedcausativebacteriaandpercentageofpatients. Table. MICsofantibacterialagentsforthecausativebacteria )S.pneumoniae Drug <_.6..5 MIC <_ Range MIC5 MIC9 LVFX CFPN-PI CDTR-PI CFDN ABPC CVA/AMPC 5 5 <_.6.5 <_.6.5 <_.6 <_.6 <_ <_.6 <_ )H.influenzae Drug <_.6..5 MIC <_ Range MIC5 MIC9 LVFX CFPN-PI CDTR-PI CFDN ABPC CVA/AMPC 8 5 <_.6 <_.6 <_ <_.5 6 <_ <_ <_ 6 )M.catarhalis Drug <_.6..5 MIC <_ Range MIC5 MIC9 LVFX CFPN-PI CDTR-PI CFDN ABPC CVA/AMPC 8 6 <_.6 <_.6 <_ <_.6.5 <_ <_ β
11 oitacifissal oitacifissal Table5. Causativebacteriadetectedatthetimeofacuteexacerbationandrecurence No. Group Exacerbation LVFX Streptococcuspneumoniae β -lactam Pseudomonasaeruginosa Moraxelacatarhalis β -lactam Haemophilusinfluenzae Haemophilusinfluenzae LVFX Moraxelacatarhalis Streptococcuspneumoniae 5 LVFX Haemophilusinfluenzae Moraxelacatarhalis 6 LVFX Haemophilusinfluenzae 7 LVFX Haemophilusparainfluenzae Streptococcuspyogenes * ThesamegeneticpaternwasshownbyPFGE. Recurence Streptococcuspneumoniae * Notdetected Moraxelacatarhalis Notdetected Haemophilusparainfluenzae Streptococcuspneumoniae Notdetected Table6. Incidenceofadversedrugreactions Group Patientsevaluatedforsafety Patientswithadversedrugreactions Incidenceofadversedrugreactions Skin n C Gastrointestinal CNS Hepatic Renal Others LVFX 96 7.% Nausea(mild:event) Vomiting(mild:event) Dulheadache(mild:event) Hepaticdysfunction(mild:events) Hepaticdysfunction(moderate:event) Renaldysfunction(mild:event) Epistaxis(mild:event) β -lactam 88.5% Redness/pruritus(mild:event) Diarhea(mild:event) Gastritis(mild:event) Table7. Incidenceofadversedrugreactionsinelderlypatients(>_ 75years) Group Patientsevaluatedforsafety Patientswithadversedrugreactions Incidenceofadversedrugreactions Skin n C Gastrointestinal Hepatic Renal LVFX.5% Hepaticdysfunction (mild:event) Renaldysfunction (mild:event) β -lactam 5.8% Redness/pruritus(mild:event) Gastritis(mild:event) S. pneumoniaeh. influenzaem. catarrhalis β S. pneumoniae H. influenzaem. catarrhalis µ H. influenzae
12 β β β β S. pneumoniaeh. influenzaem. catarrhalis Mycoplasma pneumoniaechlamydia pneumoniae Chlamydia pneumoniae Mycoplasma pneumoniaechlamydia pneumoniae
13
14 Mycoplasma pneumoniae Mycoplasma pneumoniae
15 Chlamydia pneumoniae Chlamydia pneumoniae Chlamydia pneumoniae Chlamydia pneumoniae Chlamydophila pneumoniae
16 β β β β β β β β Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis Mycoplasma pneumoniae Chlamydia pneumoniae β β
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
More information日本化学療法学会雑誌第57巻第6号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae S. pneumoniae β β H. influenzae S. pneumoniae H. influenzae M. catarrhalis Key words Otalgia Fever Item Crying,Iritation,
More information日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
More information日本化学療法学会雑誌第55巻第S-1号
µ µ Key words Streptococcus pneu- moniae S. pneumoniae µ µ I γ H H C HN F F O N O CO H H C SO H H O Fig.. ChemicalstructureofGRNX. γ γ II Haemophilus influenzae Pseudomonas aeruginosa Streptococcus intermedius
More information日本化学療法学会雑誌第65巻第4号
Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae
More information日本化学療法学会雑誌第60巻第4号
Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Key words β Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae μ μ S. pneumoniae H. influenzae S. pneumoniae
More information日本化学療法学会雑誌第57巻第4号
Streptococcus pneumoniae Haemophilus influenzae β β Key words I β Enterococcus faecium Pseudomonas aeruginosa Streptococcus pneumoniae S. pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Table.
More information日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
More information日本化学療法学会雑誌第54巻第S-1号
β β Key words β Candida krusei Candida glabrata β I β Drugadministration Baselinecharacteristics Clinicalsymptom Mycologicaltests Plasmadrugconcn Adverseevents Laboratorytests ) -leadecg Clinicalphotograph
More information日本化学療法学会雑誌第56巻第S-1号
Key words Streptococcus pneumoniae µ µ H F Cl H H N N H N F COOH O Fig.1. Sitafloxacinstructure. I γ S. pneumoniae Haemophilus influenzae Table1. Observationandtestschedule Observation/Tests Informedconsent
More information日本化学療法学会雑誌第57巻第5号
in vitro Key words Streptococcus pneumoniae β Haemophilus influenzae Escherichia coli I Table. Antibacteriallevofloxacinactivityagainstclinicalisolates Organism Year Susceptibility(%)(Numberofstrains)
More information日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
More informationTable 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
More information日本化学療法学会雑誌第56巻第3号
β Key words Candida albicans albicans Candida C. albicans Candida glabrata Candida krusei albicans Candida C. glabrata C. albicans albicans Candida β in vitro in vivo C. glabrata C. krusei I β γ µ Candida
More informationCHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
More information日本化学療法学会雑誌第57巻第1号
In vitro Streptococcus pneumoniae Escherichia coli in vitro Streptococcus pneumoniae Escherichia coli µs. pneumoniae E. coli µ Key words in vitrostreptococcus pneumoniae Escherichia coli Escherichia coli
More information日本化学療法学会雑誌第58巻第2号
Key words β Candida Table1. MCFGCPAstudygroup Investigator (representative) YoshitsuguMiyazaki NaoyukiMiyashita RyoichiAmitani KenjiOgawa AtsuyukiKurashima ToshiroKiguchi MichiakiMishima YuichiInoue HiroshiSaito
More informationCHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
More informationCHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
More information日本化学療法学会雑誌第57巻第S-2号
Key words β I Table. Observationandtestschedule Testschedule Observation/Tests Beforetreatment Endoftreatment 5 9days aftercompletion oftreatment 4 6weeks aftercompletion oftreatment Informedconsent Patientbackground
More information日本化学療法学会雑誌第54巻第1号
Chlamydophila pneumoniae Chlamydophila psittaci Mycoplasma pneumoniae Legionella pneumophila C. pneumoniae C. psittaci C. pneumoniae C. psittaci M. pneumoniae M. pneumoniae C. psittaci L. pneumophila C.
More informationFeb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
More informationFig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
More information366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
More informationCHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
More informationVOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
More informationCHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
More informationVOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More information日本化学療法学会雑誌第54巻第S-1号
β β β Key words β β I HP- -CD CHR RHC R R R R CHR R R R R RHC R R R CHR R R R RHC CHR R H CH CH Fig.. Structuralformulaofhydroxypropyl-β -cyclodextrin(hp-β -CD). CH n H β β β β Table-. Dosageandadministration(Singleadministrationstudy)
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
More informationFig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,
More informationuntitled
1988 2000 2002 2004 2006 2008 IFN Lamivudine Adefovir Entecavir 1 Total number 560 Sex (male/female) 424/136 Age (years)* 38 (15-68) Duration of treatment (weeks)* 26 (1-592) Follow-up time (years) 75(05-21
More information日本化学療法学会雑誌第65巻第3号
μ Key words Chlamydia trachomatis C. trachomatis I Table1.Observation items, categories and scores Observation item Category Score Body temperature () Lower abdominal pain Uterine corpus tenderness Condition
More informationepidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
More informationcoccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
More information208 ( 2 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 Cefditoren pivoxil (CDTR-PI) MS MS 10%
207 ( 1 ) Cefditoren pivoxil G 2010 2 2 2006 3 Cefditoren pivoxil CDTR-PI MS 10% CDTR-PI 305 2,144 2,006 1,958 1.79% 36 2,006 26 (1.30%) CDTR-PI CDTR-PI (9 mg/kg/day) 1.5 2 (2.70%) 2 (1.92%) 93.5% 1,831
More informationFig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
More informationFig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
More informationTable 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
More information日本化学療法学会雑誌第66巻第2号
173 Table 1.Detection rates of Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Ureaplasma urealyticum, Haemophilus influenzae and adenovirus from male urethritis in Urethritis No.
More information日本化学療法学会雑誌第51巻第2号
piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC
More informationVOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
More informationCHEMOTHERAPY JUNE 1986
VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml
More informationVOL.39 S-3
VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose
More informationFig. 1 Chemical structure of norfioxacin (AM-715)
Fig. 1 Chemical structure of norfioxacin (AM-715) Table 1 Serum and biliary concentration of norfloxacin (AM-715) Table 2 Protocol for clinical evaluation of norfloxacin (AM-715) in the treatment of biliary
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 STFX mg mg mg mg mg 1
June 2014 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 175 29 1 2 2 2 2 2 3 4 4 5 5 2 2 1 2 3 4 5 2014 4 15 STFX 50 mg 10% 2011 8 1 100 mg 1 1 2011 12 2013 5 226 1,186 1,089 1,069 2.11% 23/1,089 1.10% 12/1,089
More informationMIC MIC...
50 mg 10% 2.7.36 2.7.36 2.7.36... 1 1.6... 1 2.6... 3 3.6... 5 3.16... 5 3.26... 12 3.36... 16 4.6... 17 5.6... 19 6.6... 20 2.7.3.3.16-1 MIC... 9 2.7.3.3.16-2 MIC... 10 2.7.3.3.16-3 MIC E. coli... 11
More information日本化学療法学会雑誌第50巻第6号
13 11 30 14 4 22 Streptococcus pneumoniae Haemophilus influenzae amoxicillin AMPC cefditoren pivoxil CDTR AMPC 50 mg kg day CDTR 9mg kg day CDTR 18 mg kg day S. pneumoniae H. influenzae 8 17 25 1 25 S.
More information日本消化器外科学会雑誌第30巻第3号
Key words : gastric cancer, progltostic factor. multivariate analysis Factors selected after Coffelation- after Stepwise rnitrally check check H o s t l A g e C O 2 S e x C O 3 Pre-op. compliation O Treatment
More informationCHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
More informationTable 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
More informationClostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
More informationR06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
More informationCHEMOTHERAPY Table 2 Clinical response of 6059-S by infection Table 3 Effect of 6059-S on blood chemistry *Normal range : S-GOT 20 `60 mu/ml, S-GPT 5 `25 IU/L, Al-Pase 30 `85 mu/ml In oilier cases : S-GOT
More information400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
More informationThe clinical characteristics of Mycoplasma pneumoniae pneumonia in children younger than 6 years old Nobue Takeda1,2),Tomomichi Kurosaki1),Naruhiko Ishiwada2),Yoichi Kohno2) 1)Department of Pediatrics,Chiba
More informationCHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation
CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference
More information180 ( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS June 2011 A b group A Streptococcus: GAS GAS 10 meta-analysis 1) 2,3) GAS potential pathogens Tab
June 2011 THE JAPANESE JOURNAL OF ANTIBIOTICS 64 23 179 ( 63 ) A b cefditoren pivoxil 5 amoxicillin 10 1,2) 1,3) 1) 1) 1) 4) 5) 6) 7) 1) 2) 3) 4) 5) 6) 7) 2011 4 8 2007 5 2009 4 A b GAS cefditoren pivoxil
More informationTable 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
More informationVOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus
More information食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
More informationpneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia
More information一般社団法人 日本感染症学会 第89回総会資料
Longitudinal surveillance of Haemophilus influenzae isolates from pediatric patients with meningitis throughout Japan, 2000 2011 Journal of Infection and Chemotherapy Vol.19No.1 p34-41kimiko Ubukata Long-term
More information日本化学療法学会雑誌第61巻第4号
μ μ μ μ μ μ Key words I β μ Sex Age (years) Height (cm) Evaluation items Table1.Characteristics of patients 1. mg/kg/day (n14) 2.5 mg/kg/day (n9) 5. mg/kg/day (n9) Total (n32) male 12 8 7 27 female 2 1
More information日本化学療法学会雑誌第58巻第S-2号
μ Key words Streptococcus pneumoniae β Haemophilus influenzae β Moraxella Branhamella catarrhalis I F F H C SO H H O H N N N N F CO H O Fig.1. Chemicalstructureoftosufloxacintosilatehydrate. α Body weight
More informationVOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
More informationudc-2.dvi
13 0.5 2 0.5 2 1 15 2001 16 2009 12 18 14 No.39, 2010 8 2009b 2009a Web Web Q&A 2006 2007a20082009 2007b200720082009 20072008 2009 2009 15 1 2 2 2.1 18 21 1 4 2 3 1(a) 1(b) 1(c) 1(d) 1) 18 16 17 21 10
More informationTable1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
More informationCHEMOTHERAPY APR. 1984
VOL.32 S-3 CHEMOTHERAPY dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine- CHEMOTHERAPY APR. 1984 VOL.32 S-3 CHEMOTHERAPY Table 1 Implantation rates and post- implantation survival rates in females mated
More informationCHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),
More informationOsamu NEMOTO, M.D. Clinical and Bacteriological Research of Sucrose/ Povidone-Iodine Ointment (U-PASTA kowa) for Pressure Sores and Skin Ulcers Osamu Nemoto Department of Dermatology,Tonan Hosptal
More information4月号 学会特集号 122247/16)一般演題目次
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 48 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 49 60 61 62 63 64 65 66 67 68
More informationKey words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
More informationCHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
More informationTitle 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL
Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date 1958-01 URL http://hdl.handle.net/2433/111559 Right Type Departmental Bulletin
More information/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
More information日本化学療法学会雑誌第57巻第S-2号
µ µ Key words µ µ µ I Table1. Subjectprofilesin(A)singleand(B)multiple-dosestudies (A)Single-dosestudy Age (yr) Height (cm) Bodyweight (kg) BMI (kg/m ) Ccr(Cockcroft) (ml/min) Ethnicity dose(mg) n 5 5.1±.,3
More informationKey words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
More informationStreptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
More informationuntitled
19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- twatanab@oncoloplan.com http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase
More information日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
More informationTable 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
More information第65回日本化学療法学会東日本支部総会 抄録
鍵 76 Clostridioides difficile C. difficile 77 γ γ Mycobacterium avium 78 79 Clostridium difficile Treponema pallidum 80 81 82 in vitro in vitro 83 鍵 Treponema pallidum 84 Chlamydia trachomatis Mycoplasma
More informationCHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
More informationA Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, School of Medicine, Tokushima University, Tokushima Fetal
More information21 Effects of background stimuli by changing speed color matching color stimulus
21 Effects of background stimuli by changing speed color matching color stimulus 1100274 2010 3 1 ,.,,.,.,.,,,,.,, ( FL10N-EDL). ( 10cm, 2cm),,, 3.,,,, 4., ( MSS206-402W2J), ( SDM496)., 1200r/min,1200r/min
More informationVOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT
More informationKey words: Antibodies to Leptospira, Tokyo, Uveitis
Key words: Antibodies to Leptospira, Tokyo, Uveitis Fig. 1 Distribution of Antibody Titers in Age Decade Fig. 3 Distribution of Antibody Titers in each Strain Fig. 2 Correlation between Antibody Titers
More informationSurvey of the Incidence of Dry Cough Caused by ACE Inhibitors MOTOHIRO YAGI*, MIKIO SAITO, MANABU ABE and KATSUJI UNO Pharmacy, Suibarago Hospital õ Received October 24, 1996 Accepted September 3, 1997
More informationp., a, b, identified resistance p. Iwata, Dorsey, Slifer, Bauman, & Richman, / challenging behavior Matson, function or functional challenging behavio
A Functional Analysis and Improvement of Resistance in Behavioral Psychotherapy: A Case Study. Takashi Muto & Yukari Umezawa Abstract Study objective: To improve resistance in behavioral psychotherapy
More informationFig. 1 Chemical structure of Flurbiprofen Molecular formula : C1S H13 F02 Molecular weight : Chemical name : 2-( 2 -fluoro - 4 -biphenyly1 ) pr
Key words : Flurbiprofen, Acute Upper Respiratory Tract Inflammation, Double-Blind Clinical Evaluation Fig. 1 Chemical structure of Flurbiprofen Molecular formula : C1S H13 F02 Molecular weight : 244.27
More informationStaphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
More informationCHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
More information